Novavax has favorable interim results from Phase I/IIa human clinical trial |
|
|
|
Published
:
Thu, 20 Dec 2007 14:22
|
NEW YORK (Thomson Financial) - Novavax Inc. Thursday said it had favorable interim results from a Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate.Interim results indicate that the vaccine was well-tolerated in 70 healthy adults aged 18 to 40 who received two doses of either the vaccine candidate or a placebo.'These data support the vaccine as part of our contribution to pandemic flu preparedness planning. Novavax has the potential to offer a safe and immunogenic vaccine that can be created in cell culture within 12 weeks of the emergence of a pandemic strain,' the company said.Shares of the Rockville, Md.-based drug delivery and vaccine development company closed Wednesday at $3.38.Melinda Peermp/pcCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1449.80 |
+51.73 (
3.63 %)
|
| SYMBOL (
2008-12-02 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
1347.00 |
+51.00 (
4.02 %)
|
| SYMBOL (
2008-12-02 )
|
| LAST |
CHANGE
|
|
IBM
(
4:01pm ) |
|
79.84 |
+2.94 (
3.78 %)
|
| SYMBOL (
2008-12-02 )
|
| LAST |
CHANGE
|
|
GOOGLE
(
4:00pm ) |
|
275.11 |
+9.12 (
3.37 %)
|
|
|
Print this Story
Novavax sees favorable results from preclinical studies of seasonal flu vaccine 